Brown & Brown BRO
Financial Services · Insurance - Brokers · Synthos Deep Dive · 2026-07-03
The Overview
Brown & Brown is an insurance broker — the middleman that helps businesses and individuals buy insurance and collects a commission on every policy. It doesn't take on the insurance risk itself; it just earns fees, which makes it a steady, cash-generative business. It grows two ways: selling more each year to existing and new clients ("organic" growth), and buying up smaller brokers (it has done this for decades).
Two things to know right now. First, the company just made its biggest purchase ever and borrowed a lot to do it, so it carries more debt than usual. Second — and this is the worry — its organic growth just dropped to zero in the most recent quarter, meaning all its growth came from acquisitions, not from the underlying business getting bigger. The stock has already fallen about 36% from its high, so it's no longer expensive, but it's not obviously cheap either.
Our verdict is Watch — a good company we'd want to own at the right moment, but not today. We want to see the organic growth engine restart first.
Here's what our three scores mean in everyday terms:
- Downside Risk 6/10 (a bit above middle). The business is stable and the stock doesn't swing wildly, but the extra debt from the big deal and the stalled growth raise the stakes.
- Growth Quality 6/10 (decent). Profitable and cash-generative, but lately the growth has been bought rather than earned — that's lower quality.
- Exponential Potential 3/10 (low). This is a mature, methodical compounder. It won't multiply your money quickly.
The one big worry: if organic growth stays at zero, the whole "buy-and-grow" machine loses its shine, and a stock priced for steady growth would have to re-rate lower.
Putting a number on it: our fair-value estimate is $84 against a current price of $73.31 — real upside if our numbers are right.
Our summary metrics
Low beta (0.62) & recurring commissions, but net-debt/EBITDA jumped to 3.3× post-Accession and organic went flat.
~10% forward revenue CAGR & 33% EBITDA margins, but growth is now M&A-funded and Q1'26 organic was 0.0%.
Mature ~$24B roll-up broker; steady compounder, not an exponential — decelerating organic caps the upside.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Mature ~$24B roll-up broker; steady compounder, not an exponential — decelerating organic caps the upside.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $92.83 (high $120 / low $62; 10 Buy · 20 Hold · 0 Sell — consensus Hold) — context, not our anchor |
| Valuation | 22× trailing GAAP EPS · 15.5× FY26E · 14.3× FY27E · 13.3× FY28E · EV/S 4.8× · EV/EBITDA 14.3× |
| Technicals | Mixed — $70, −36% off 52-wk high, below the 200-DMA ($73), but RSI 80 (overbought) on a sharp bounce off the low |
| Conviction | Low — 0 expert voices, 0 traceable claims; call rests entirely on fundamentals + quant |
| Position sizing | Small / starter only (≤2%) until organic growth re-accelerates and leverage comes down |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for BRO — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $73.31, 6% above the 50-day average ($69), 5% above the 200-day average ($70) — an uptrend. 24% below the 52-week high of $97, 35% above the 52-week low of $54.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $73.31 is currently inside the band (band $69–$74).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 58.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.05, negative momentum.
Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago
Solid = BRO · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Brown & Brown, Inc. (NYSE: BRO), founded 1939 and headquartered in Daytona Beach, Florida, is one of the largest insurance brokerage firms in the world. It does not underwrite risk — it distributes property & casualty, employee-benefits, personal and specialty insurance, earning commissions and fees. That makes it a capital-light, recurring-revenue business with high margins (EBITDA margin ~33% TTM) and low cyclicality. CEO is J. Powell Brown (founding-family lineage). Fiscal year ends December 31.
Historically BRO reported four segments — Retail, National Programs, Wholesale Brokerage, and Services. Note the FMP product segmentation is inconsistent year-to-year and, for FY2025, collapses into a re-cut "Retail $3.41B / Specialty Distribution $2.41B" split — a reporting reorganization, not comparable to the prior four-segment view. Treat the segment lines below as directional.
Revenue mix (from filings via FMP):
- By product (FY2025 re-cut): Retail $3.41B (59%) · Specialty Distribution $2.41B (41%). (FY2024 under the old cut: Retail $2.73B, National Programs $1.40B, Wholesale Brokerage $0.62B.)
- By geography (FY2025): United States $5.06B (~89%) · United Kingdom $0.60B (~11%), with small Canada/Ireland operations. The business is overwhelmingly US-domestic — a concentration but also insulation from FX and foreign-market risk.
The strategic engine to understand is the M&A roll-up: BRO compounds by acquiring smaller agencies, and in 2025 it closed its largest deal ever (Accession Risk Management / RSC), which is why FY2025 revenue jumped +26.6% while organic growth was far lower.
2. The expert thesis (no KB coverage)
There is no expert coverage for BRO in the Synthos knowledge base — total_claims = 0, zero net-bullish voices, zero cautionary voices. No independent analyst or investor claims were available to reconcile, so this note carries no conviction premium: the verdict is driven entirely by the fundamentals, the analyst-estimate consensus, and our own scoring framework.
Because we will not fabricate conviction, the honest read is: this is a quant/fundamental call, not a conviction call. For context only (and explicitly not our anchor), the sell-side is lukewarm — consensus "Hold," 10 Buy / 20 Hold / 0 Sell, price target $92.83. When 20 of 30 analysts sit on Hold, that itself is a signal the market is waiting for organic growth to prove itself.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 6 · Moderate-High | Low beta (0.62), recurring commissions and modest drawdown-recovery cushion the downside — but net-debt/EBITDA jumped to ~3.3× after the ~$7.8B Accession deal, and organic growth going to 0.0% removes the safety margin that justified a premium multiple. |
| Growth Quality | 6 · Moderate | ~33% EBITDA margins, high FCF conversion and a decades-long compounding record are real, but forward growth is now M&A-funded (goodwill doubled to $15B) rather than organic, and ROIC (~5.9%) and ROE (~9.3%) are unspectacular after the goodwill build. |
| Exponential Potential | 3 · Low | A mature ~$24B roll-up broker in a slow-growth industry. ~10% forward revenue CAGR with decelerating organic and a large base — a steady compounder, not an exponential. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Accession integrates cleanly, organic growth re-accelerates to mid-single digits, and P&C pricing stays firm. FY27E EPS beats to ~$5.10 (vs $4.89 cons); the market pays back up toward BRO's historical premium at ~21×. | ~$106 (+51%) |
| Base (our anchor) | Estimates roughly hit — FY27E EPS ~$4.89; organic recovers to low-single digits; a de-risked but no-longer-premium multiple of ~17× as leverage normalizes. | ~$84 (+20%) |
| Bear | Organic stays flat, integration friction and higher interest expense weigh on EPS; FY27E EPS misses to ~$4.50 and the multiple de-rates to ~14× as the roll-up premium erodes. | ~$63 (−10%) |
Synthos fair value = the base case, ~$84 (+20%), with the full $60–$106 span as the honest range. Our base sits just below the Street's $92.83 consensus — we apply a more cautious multiple given the organic stall and elevated leverage. Note our bear (~$63) essentially matches the Street's low target ($62). This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers-from-here). BRO is a mature compounder well past any acceleration:
- Forward growth: revenue CAGR FY25→FY28E ~9.8% ($5.96B → $7.88B); EPS CAGR (GAAP FY25 $3.16 → FY28E $5.27) ~18.6%, though much of that is margin/leverage-driven off a depressed FY25 GAAP base rather than volume.
- Acceleration (the 2nd derivative) is negative on what matters: organic revenue growth was 0.0% in Q1'26 (management's own reconciliation: Organic Revenue with Contingents +2.2%). Reported growth is being carried by acquisitions. The engine is decelerating on the metric the market rewards.
- Room to run: the US insurance-brokerage market is large and fragmented (supporting continued tuck-in M&A), but at ~$24B market cap in a low-single-digit-organic-growth industry, there is no realistic path to a fast multibagger. The addressable roll-up runway extends duration, not slope.
- Reinvestment runway: genuine — BRO can keep deploying FCF and debt into acquisitions for years. But debt-funded roll-ups compound steadily, not exponentially, and each deal adds goodwill and integration risk.
Exponential Potential: Low (3/10). Own BRO — if you own it — for durable mid-teens earnings compounding at a reasonable price, not for a fast multibagger. The flat organic print is exactly why this scores at the low end.
5. Financials (real numbers — FMP annual/quarterly + Q1'26 8-K)
- Revenue: FY25 $5.96B, +26.6% (FY24 $4.71B, +12.0% on FY23 $4.20B). But the FY25 jump is acquisition-driven — Q1'26 total revenue +35.4% YoY with flat organic confirms the mix.
- Quarterly trajectory: Q1'25 $1.39B → Q2 $1.25B → Q3 $1.61B → Q4 $1.67B → Q1'26 $1.90B (+35.4% YoY, but 0.0% organic).
- Margins: gross ~59% TTM, EBITDA margin ~33.6% TTM, operating ~27%, net ~17.9% TTM. Management's adjusted EBITDAC margin was 38.5% in Q1'26 (roughly flat YoY) — best-in-class for a broker.
- Earnings: FY25 net income $1.04B, EPS diluted $3.16 (GAAP; depressed by amortization from the deal). FY24 EPS $3.46. Q1'26 diluted GAAP EPS $1.06 (−7.8% YoY on higher amortization/share count) vs adjusted $1.39 (+7.8%) — the GAAP/adjusted gap is now wide because of acquisition amortization.
- Cash flow: FY25 operating CF $1.45B, capex only ~$68M (capital-light), FCF ~$1.38B (FCF yield ~6.2%). High-quality cash conversion.
- Balance sheet — the flag: FY25 net debt $6.84B (up from $3.39B in FY24), net-debt/EBITDA ~3.3× (up from ~2.0×). Goodwill $15.1B (from $8.0B) and intangibles $4.9B now total ~$20B of a $30B balance sheet — tangible book value is negative. Interest coverage ~6.8× is still comfortable, but the leverage step-up is real and must be watched.
6. Valuation — priced in or room?
After a ~36% drawdown from its 52-week high, BRO no longer trades at its historical premium. On live consensus the forward P/E is 15.5× (FY26E) → 14.3× (FY27E) → 13.3× (FY28E) — reasonable for a mid-teens-EPS-growth broker, and well below the mid-20s multiples BRO commanded for much of the last decade. EV/EBITDA is 14.3× and EV/sales 4.8×. On trailing GAAP it looks richer (22×) only because deal amortization is depressing GAAP EPS.
The bull case is that the de-rating already happened and you're buying a quality franchise at a discount to its own history. The bear case is that the de-rating is justified — the premium multiple was paid for durable organic growth, and organic is now zero. Street targets (context): consensus $92.83, high $120, low $62. Our ~$84 base is below consensus because we apply a more conservative ~17× multiple until organic re-accelerates and leverage normalizes. Not obviously cheap, not expensive — fairly priced for a Watch.
7. Technicals (from the tech block)
- Trend: mixed-to-weak. $70 sits above the 50-DMA ($59.6) after a sharp bounce, but still below the 200-DMA ($73.4) — the intermediate trend has not yet turned up.
- Location: −35.6% off the 52-week high ($108.7) and only +28.7% off the low ($54.4); max drawdown from peak was −43.7%. This is a broken-then-recovering chart, not a leadership uptrend.
- Momentum: RSI(14) 79.6 — overbought (>70). MACD is positive (+2.04), consistent with the recent bounce, but the overbought RSI argues against chasing here.
- Relative strength (the tell): BRO −35.7% 12-mo vs SPY +20.6% and QQQ +30.3% — massive underperformance over the year. Shorter term it has stabilized (+8.7% 3-mo) but still lags SPY (+13.7%) and QQQ (+22.0%).
- Read: technicals do not confirm a fresh uptrend — a deeply underperforming name bouncing into overbought territory below its 200-DMA. If adding, waiting for either a pullback that works off the overbought RSI or a decisive reclaim of the 200-DMA (~$73) is the lower-risk entry.
8. Moat & competitive position
BRO's moat is scale, distribution density, and a disciplined acquisition machine in a fragmented industry. Insurance brokerage is structurally attractive: recurring commissions, negative working-capital dynamics (fiduciary float), low capital intensity, and pricing tied to insurance rates and exposure growth rather than the economic cycle. Switching costs are moderate (relationship- and service-driven) and the industry consolidates steadily, favoring well-capitalized acquirers. BRO's edge is a long track record of buying agencies accretively and integrating them into a lean, high-margin platform.
The limits: the moat protects margins and durability, not growth rate. Organic growth ultimately tracks insurance pricing (currently softening in parts of P&C) and client exposure units. When organic stalls, as it just did, the model leans harder on M&A — which brings leverage and integration risk.
Peer set (market cap, FMP): Willis Towers Watson $27B (closest broker comp), W. R. Berkley $27B, Markel $25B, Cincinnati Financial $30B, Cboe Global Markets $26B, plus several banks the screen lumps in (Truist $64B, Fifth Third $52B, Huntington $36B, Futu $13B). The most relevant true comps are the brokers/specialty insurers (WTW, WRB, MKL); against WTW, BRO historically carried a growth premium that has now compressed.
9. Management, capital allocation & guidance
- Capital allocation: the defining choice is debt-funded M&A — ~$7.8B of acquisitions in FY25 (Accession/RSC) funded by ~$8.1B of net debt issuance, pushing net-debt/EBITDA to ~3.3×. A modest, steadily-growing dividend (~0.9% yield, ~18% payout) and only token buybacks (~$100M) round it out. This is a grow-by-acquiring allocator, not a return-of-capital story.
- Insider activity: the most recent transactions are directors buying — director Joia Johnson purchased at $58.05 (2026-06-09) and director H. Palmer Proctor purchased 2,000 shares at $57.10 (2026-05-05), alongside routine annual equity awards to the board. Open-market director buying near the lows is a modestly encouraging (not decisive) signal.
- Management's own guidance (half-weighted — their own book): the Q1'26 earnings release (SEC 8-K, filed 2026-04-27) is a genuine results release, but it contains no explicit forward revenue or EPS guidance — BRO does not issue numeric quarterly/annual guidance. What management did say is directional and self-interested: CEO J. Powell Brown noted teammates "continue to deliver for our customers in a challenging growth environment" — an unusually candid acknowledgment of the soft organic backdrop. Management reported Q1'26 total revenue +35.4%, flat organic, Organic Revenue with Contingents +2.2%, and adjusted EBITDAC margin 38.5%. Numeric forward guidance was not available in the filing; we do not fabricate it.
10. Catalysts & what to watch
- Next earnings: 2026-07-27 (Q2'26; Street EPS $1.09, revenue ~$1.72B). The line that matters: organic revenue growth — does it turn positive off the Q1'26 flat print?
- Accession/RSC integration: margin and cross-sell evidence that the largest-ever deal is delivering; watch for any earn-out or integration-cost surprises.
- Deleveraging: net-debt/EBITDA trending back toward ~2.5× would restore balance-sheet flexibility and support a higher multiple.
- P&C pricing cycle: softening commercial rates are a headwind to organic; firming rates are a tailwind.
- Continued M&A cadence: the roll-up engine — but each deal now adds to an already-elevated leverage base.
Thesis tripwires (what would change the call): two more quarters of ~0% organic (→ downgrade toward Avoid on multiple risk); a deleveraging path that stalls above ~3.3×; or, on the upside, organic re-accelerating to mid-single digits with leverage falling (→ upgrade toward Buy — Tactical).
11. Key risks
- Organic growth stall (the central risk): organic was 0.0% in Q1'26. If it persists, the roll-up premium erodes and the multiple de-rates.
- Leverage / integration: net-debt/EBITDA ~3.3× post-Accession; goodwill + intangibles ~$20B and negative tangible book. Integration missteps or rising rates raise interest cost and risk.
- Insurance pricing cycle: commissions track P&C rates; a softening cycle pressures organic revenue directly.
- Acquisition dependence: growth increasingly requires deals; a scarcity of accretive targets or overpaying would compress returns on capital (ROIC already ~5.9%).
- Valuation is only "reasonable," not cheap: at 14–15× forward with decelerating organic, there is limited margin of safety if estimates come down.
- No expert coverage: we have zero KB conviction on this name — a genuine information gap that keeps our confidence low.
12. Verdict, position sizing & monitoring
Watch. Brown & Brown is a genuinely high-quality, low-beta, cash-generative broker with a strong long-term compounding record — but three things keep us from a Buy today: (1) organic growth has gone to zero (Q1'26 0.0%), the one metric that justified its historical premium; (2) the balance sheet has levered up to ~3.3× net-debt/EBITDA after the largest acquisition in its history; and (3) we have no expert coverage to lean on, so conviction is low by construction. The stock has already de-rated ~36% and screens fairly at 14–15× forward, but "fair" is not "compelling," and the technicals (below 200-DMA, RSI 80) argue against chasing the bounce.
- Sizing: if owned at all, starter-only, ≤2% — a name to accumulate on evidence (organic re-accelerating, leverage falling), not to load up on today.
- Monitoring: re-underwrite on the §10 tripwires; the 2026-07-27 print is the key near-term test. Encouraging that directors were buying near the lows.
- Single biggest risk: organic growth staying flat — if it does, both the multiple and the roll-up model come under pressure.
This verdict is logged as a tracked Synthos call as of 2026-07-03 at $70.00.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — there is no expert coverage for BRO in the Synthos knowledge base. The verdict is explicitly fundamentals- and quant-driven; no conviction premium is applied and none is claimed. Fabricated conviction is structurally impossible (claim-ID reconciliation).
- Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03. Forward figures are analyst consensus (FMP), labeled as estimates.
- Segment caveat: FMP product segmentation is re-cut year-to-year (FY25 "Retail/Specialty Distribution" is not comparable to the prior four-segment view) — treated as directional.
- Management caveat: BRO issues no numeric forward guidance; the Q1'26 release is a results release. Management's directional commentary is its own book, half-weighted by design.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").